CD38 and Miyoshi myopathy: Thus, it seems possible to use CD38-directed antibodies to target not only MM-cells but also immunosuppressive cells, to restore the preexisting anti-MM T-cell responses in the BM-ME even after immune checkpoint blockade [26].